Iopamidol_COA_14714_MedChemExpress
Resiquimod_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Resiquimod is a Toll–like receptor 7 and 8 (TLR7/TLR8) agonist that induces the levels of cytokines such as TNF–α, IL–6 and IFN–α.In Vitro: Resiquimod (R–848) induces both hapten– and allergen–specific circulating T cells, including TH2 effectors, to produce IFN–γ and even to lose the ability to produce IL–4[2]. Resiquimod (R848) enhances PBL proliferation in a dose–dependent manner,and increases the number of BrdU–positive cells in BrdU incorporation assay. Cells treated with R848 exhibits significantly increased (3.5–fold) luciferase (a reporter of NF–κB activity) activity [3].In Vivo: Resiquimod (R–848) (50 μg/bird, i.m. route) significantly up–regulates the expression of IFN–α, IFN–β, IFN–γ, IL–1β, IL–4,iNOS and MHC–II genes in SPF chicken [1].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[3]For luciferase assay, FG–9307 cells are transfected with the firefly NF–κB–specific luciferase reporter vector pNFκB–Met–Luc2. Transfection efficiency is monitored by co–transfection with the pSEAP2 control vector, which constitutivelyexpresses the human secreted enhanced alkaline phosphatase (SEAP). Then the cells are treated with Resiquimod (R848, 1 μg/mL), CQ (10 μM), CQ plus R848 or PBS and incubated at 22°C for 24 h. The culture medium of the transfectants is then analyzed for luciferase activity and SEAP activity using Luciferase Assay Kit and the Great EscAPe? SEAP Chemiluminescence Detection Kit, respectively. The assay is performed three times.Cell Assay: Resiquimod is dissolved in DMSO.[3]For inhibition of lysosomal acidification, cells are incubated with 10 μM CQ for 1 h before Resiquimod (R848) treatment. After treatment, 20 μL of 5 mg/mL MTT is added to the plate. The plate is incubated at 22°C for 4 h, and 200 μL dimethyl sulfoxide is added to the plate to dissolve the reduced formazan. The plate is then read at 490 nm with a microplate reader. To determine the effect of Myd88 inhibition on R848–induced cell proliferation, the Myd88 inhibitor Pepinh–MYD and the control peptide Pepinh–Control are added to PBL at the concentration of 50 μM, and the plate is incubated at 22°C for 6 h.After incubation, the cells are treated with R848 and subjected to MTT assay as above. To determine the effect of NF–κB inactivation on R848–induced cell proliferation, BAY–11–7082, an irreversible inhibitor of IκB–α phosphorylation, is added to the cells at the concentration of 1 μM, and the plate is incubated at 22°C for 1 h. After incubation, the cells are treated with R848 and subjected to MTT assay as earlier. All experiments are performed three times.Animal Administration: Resiquimod is dissolved in PBS.[1]A total of 40 SPF chickens of two–week old are allotted to one of the following four experimental groups (n=10/group): Group A: PBS control; Group B: inactivated NDV vaccine; Group C:commercial oil adjuvanted inactivated NDV vaccine prepared from lentogenic strain and Group D: combination of inactivated NDV vaccine and R–848 (50 μg/bird). Vaccine or PBS is administered by intramuscular route in the thigh muscle. A booster dose is given 14–day post immunization (d.p.i). Two weeks post–booster, experimental SPF birds are challenged with velogenic strain of NDV (105 ELD 50 per bird) intramuscularly. Clinical signs and mortality are observed daily till 14 day post–challenge (d.p.c).Cloacal swabs (n=6/group) are collected from the birds on day 0, 4, 7 and 14 post–challenge and inoculated into 10–day oldProduct Name:Resiquimod Cat. No.:HY-13740CAS No.:144875-48-9Molecular Formula:C 17H 22N 4O 2Molecular Weight:314.38Target:Toll–like Receptor (TLR)Pathway:Immunology/Inflammation Solubility:DMSO: ≥ 30 mg/mLembryonated chicken eggs (n=3 eggs/sample) through intra–allantoic route. Three day post–inoculation, the allantoic fluid is checked for the NDV growth by spot haemagglutination using 10% chicken RBC.References:[1]. Sachan S, et al. Adjuvant potential of resiquimod with inactivated Newcastle disease vaccine and its mechanism of action in chicken. Vaccine. 2015 Aug 26;33(36):4526–32.[2]. Brugnolo F, et al. The novel synthetic immune response modifier R–848 (Resiquimod) shifts human allergen–specific CD4+ TH2 lymphocytes intoIFN–gamma–producing cells. J Allergy Clin Immunol. 2003 Feb;111(2):380–8.[3]. Zhou ZX, et al. Immune effects of R848: evidences that suggest an essential role of TLR7/8–induced, Myd88– and NF–κB–dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus). Dev Comp Immunol. 2015 Mar;49(1):113–20.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
XL-147_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :XL-147Catalog No. :HY-16526CAS No. :934526-89-31.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4),H302Acute aquatic toxicity (Category 1),H400Chronic aquatic toxicity (Category 1),H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effectsPrecautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents/ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:SAR245408; XL 147; XL147; SAR⁻245408; SAR 245408; pilaralisibFormula:C25H25ClN6O4SMolecular Weight:541.02CAS No. :934526-89-34. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 9Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutantIATAUN number: 3077Class: 9Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
一甲基澳瑞他汀 e 化学结构-概述说明以及解释
一甲基澳瑞他汀e 化学结构-概述说明以及解释1. 引言1.1 概述一甲基澳瑞他汀（Simvastatin）是一种广泛应用于临床治疗高胆固醇血症和心血管疾病的药物。
它属于被称为他汀类药物的一员，是一种竞争性抑制HMG-CoA还原酶的药物，通过降低胆固醇的合成来达到降低血浆胆固醇的效果。
随着现代生活方式的改变和不良饮食习惯的普遍存在，高胆固醇血症在全球范围内变得越来越普遍。
该疾病不仅与心血管疾病的发展密切相关，还可能导致其他严重的健康问题，如动脉粥样硬化和心肌梗死等。
一甲基澳瑞他汀由黄曲霉属真菌产生，即通过天然发酵法生产得到。
然而，为了提高其药代动力学性质和治疗效果，科学家们通过改进和优化合成方法，合成了合成一甲基澳瑞他汀。
现在，一甲基澳瑞他汀已经成为一种被广泛研究和临床使用的药物。
在本篇文章中，我们将介绍一甲基澳瑞他汀的化学结构、合成方法、性质与用途等方面的内容。
通过深入了解一甲基澳瑞他汀，我们可以更好地理解它在治疗高胆固醇血症和心血管疾病方面的作用机制，并有望对该药物的未来发展提供一定的启示。
在接下来的章节中，我们将详细介绍一甲基澳瑞他汀的化学结构、合成方法以及它在临床上的广泛用途。
最后，我们将总结这篇文章的主要观点，并对一甲基澳瑞他汀的未来进行展望。
通过本文的阅读，读者将能够全面了解一甲基澳瑞他汀，为今后的相关研究和临床实践提供有益的指导与参考。
文章结构部分的内容如下：1.2 文章结构本文主要包含以下几个部分：引言、正文和结论。
引言部分通过概述一甲基澳瑞他汀的化学结构和合成方法，介绍背景知识和研究意义。
此外，本部分还会明确文章的目的，即对一甲基澳瑞他汀进行全面的分析和探讨。
正文部分将围绕一甲基澳瑞他汀展开讨论。
首先，我们将介绍一甲基澳瑞他汀的化学结构，包括其分子式、分子量等信息，并通过图表等形式直观地展示其结构。
其次，我们将详细介绍一甲基澳瑞他汀的合成方法，包括起始原料的选择、反应步骤和条件等。
GSK1904529A_1089283-49-7_MSDS_MedChemExpress
MSDS1 Composition7 Accident Release MeasureProduct Name:GSK1904529AChemical Name:PROCEDURE(S) OF PERSONAL PRECAUTION(S)-Wear respirator, chemical safety goggles, rubber boots, and heavyrubber gloves.METHODS FOR CLEANING UP-Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area andwash spill site after material pickup is complete.Benzamide, N-(2,6-difluorophenyl)-5-[3-[2-[[5-ethyl-2-methoxy-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-methoxy-CAS No.:1089283-49-78 Accident Release MeasureAppearance:Light yellow to yellow(solid)Formula:C44H47F2N9O5S 9 Toxicological InformationSolubility:To the best of our knowledge, the chemical, physical, andtoxicological properties have not been thoroughly investigated.No data available.p p p p DMSO2 Handling and Storage10 Regulary Information3 Stability and Reactivity11Disposal ConsiderationsCLASSIFICATION- Substance not yet fully tested.SAFETY PHASES- 26-36 (In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing.) 36/37/38 (Irritating to eyes,respiratory system and skin.)STABILITY- Stable under normal handling conditions.HANDLING- Do not breathe dust. Avoid contact with eyes,skin,and clothing.Avoid prolonged or repeated exposure.STORAGE- Store in a properly sealed container store at -20℃,shelflife is 2 years.11 Disposal Considerations 4 Hazards Identification12 Transport Information5First Aid RID/ADR- Non-hazardous for road transport. IMDG- Non-hazardous for sea transport.IATA - Non-hazardous for air transport.As specific country, federal, state and local environmentalregulations vary and change frequently we suggest you contact a local, authorized waste disposal contractor for adequate disposal.Special indication of hazards to humans and the environment.Irritating to eyes, respiratory system and skin.MATERIALS TO AVOID- Strong oxidizing agents.REACTIVITY- May emit toxic gasses like Carbon monoxide,Carbon dioxide, Nitrogen oxides upon thermal decomposition.5 First Aid13 Other InformationThe above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Medchemexpress LLC shall not be held liable for any damage resulting from h dli f t t ith th b d tINHALATION- If inhaled, remove to fresh air. If not breathing give, artificial respiration. If breathing is difficult, give oxygen.SKIN CONTACT- In case of contact, immediately wash skin withsoap and copious amounts of water.EYE CONTACT- In case of contact, immediately flush eyes withcopious amounts of water for at least 15 minutes.INGESTION- If swallowed, wash out mouth with water provided person is conscious. Call a physician.6 Fire Fighting Measureshandling or from contact with the above product.EXTINGUISHING MEDIA Water spray- Carbon dioxide, dry chemical powder, or appropriate foam.SPECIAL RISKS Specific Hazard(s)- Emits toxic fumes under fire conditions. SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS Wear self-contained breathing apparatus and protective clothing Caution: Not fully tested. For research purposes onlyMedchemexpress LLCto prevent contact with skin and eyes.18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。
Alvespimycin hydrochloride_467214-21-7_MSDS_MedChemExpress
MSDS1 Composition7 Accident Release MeasureProduct Name:Alvespimycin hydrochlorideChemical Name:PROCEDURE(S) OF PERSONAL PRECAUTION(S)-Wear respirator, chemical safety goggles, rubber boots, and heavyrubber gloves.METHODS FOR CLEANING UP-Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area andwash spill site after material pickup is complete.Geldanamycin, 17-demethoxy-17-[[2-(dimethylamino)ethyl]amino]-, hydrochloride (1:1)CAS No.:467214-21-78 Accident Release MeasureAppearance:purple(solid)Formula:C32H49ClN4O89 Toxicological InformationSolubility:To the best of our knowledge, the chemical, physical, andtoxicological properties have not been thoroughly investigated.No data available.p p p p DMSO ≥130mg/mL Water ≥2.8mg/mLEthanol <0.8mg/mL2 Handling and Storage10 Regulary Information3 Stability and Reactivity11Disposal ConsiderationsCLASSIFICATION- Substance not yet fully tested.SAFETY PHASES- 26-36 (In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing.) 36/37/38 (Irritating to eyes,respiratory system and skin.)STABILITY- Stable under normal handling conditions.HANDLING- Do not breathe dust. Avoid contact with eyes,skin,and clothing.Avoid prolonged or repeated exposure.STORAGE- Store in a properly sealed container store at -20℃,shelflife is 2 years.11 Disposal Considerations 4 Hazards Identification12 Transport Information5First Aid RID/ADR- Non-hazardous for road transport. IMDG- Non-hazardous for sea transport.IATA - Non-hazardous for air transport.As specific country, federal, state and local environmentalregulations vary and change frequently we suggest you contact a local, authorized waste disposal contractor for adequate disposal.Special indication of hazards to humans and the environment.Irritating to eyes, respiratory system and skin.MATERIALS TO AVOID- Strong oxidizing agents.REACTIVITY- May emit toxic gasses like Carbon monoxide,Carbon dioxide, Nitrogen oxides upon thermal decomposition.5 First Aid13 Other InformationThe above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Medchemexpress LLC shall not be held liable for any damage resulting from h dli f t t ith th b d tINHALATION- If inhaled, remove to fresh air. If not breathing give, artificial respiration. If breathing is difficult, give oxygen.SKIN CONTACT- In case of contact, immediately wash skin withsoap and copious amounts of water.EYE CONTACT- In case of contact, immediately flush eyes withcopious amounts of water for at least 15 minutes.INGESTION- If swallowed, wash out mouth with water provided person is conscious. Call a physician.6 Fire Fighting Measureshandling or from contact with the above product.EXTINGUISHING MEDIA Water spray- Carbon dioxide, dry chemical powder, or appropriate foam.SPECIAL RISKS Specific Hazard(s)- Emits toxic fumes under fire conditions. SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS Wear self-contained breathing apparatus and protective clothing Caution: Not fully tested. For research purposes onlyMedchemexpress LLCto prevent contact with skin and eyes.18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。
Ticagrelor_274693-27-5_DataSheet_MedChemExpress
Product Name:Ticagrelor CAS No.:274693-27-5Cat. No.:HY-10064Product Data SheetMWt:522.57Formula:C23H28F2N6O4S Purity :>98%Solubility:DMSO 105 mg/ml; Water <1 mg/mly Mechanisms:Biological Activity:Ticagrelor(AZD 6140)is the first reversibly binding oral P2Y12receptor antagonist(Ki=2nM)alsoPathways:GPCR/G protein; Target:P2Y Receptor g ;g Ticagrelor(AZD-6140) is the first reversibly binding oral P2Y12 receptor antagonist(Ki= 2 nM), also inhibits CYP2C9 and midazolam 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively.IC50 value: 2 nM (Ki, P2Y12 receptor); 10.5 uM(CYP2C9)Target: P2Y12 receptor; CYP2C9in vitro: Ticagrelor is an active drug which, does not require metabolic activation after intestinal absorption. It does not compete directly with ADP at the ADP binding site but occupies an adjacent binding site and acts in an allosteric way, resulting in a reversible conformational change of the receptor. Ticagrelor binds reversibly to the receptor and exhibits rapid onset and offset of effect.Binding studies in rh-P2Y12 receptor-transfected CHO-K1 cells indicate that ticagrelor exhibits References:[1]. Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes By Lombo, Bernardo;Diez, Jose G.From Core Evidence (2011), 6, 31-42.g p gpotent, rapid, and reversible binding, with a Kd of 10.5 nM, a kon (association constant) of 0.00011/(nM...[2]. Serebruany VL.Ticagrelor FDA approval issues revisited.Cardiology. 2012;122(3):144-7.[3]. Jeong YH, Bliden KP , Antonino MJ, Park KS, Tantry US, Gurbel efulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor andclopidogrel therapies.Am Heart J. 2012 Jul;164(1):35-42.[4]. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC,Makris G Damelou A Tsigkas G Hahalis G Davlouros P Caution: Not fully tested. For research purposes onlyMedchemexpress LLCMakris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary inte...18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。
AG-490_133550-30-8_DataSheet_MedChemExpress
Product Name:AG-490CAS No.:133550-30-8Cat No :HY 12000Product Data SheetCat. No.:HY-12000MWt:294.30Formula:C17H14N2O3Purity :>98%DMSO 57mg/mLWaterSolubility:Mechanisms:Pathways:JAK/STAT; Target:EGFRPathways:JAK/STAT; Target:JAKPathways:Protein Tyrosine Kinase/RTK; Target:EGFR Pathways:Protein Tyrosine Kinase/RTK;Target:JAKDMSO ≥57mg/mL Water <1.2mg/mL Ethanol ≥8mg/mLBiological Activity:AG-490 is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). Inhibitor of JAK2, JAK3/STAT, JAK3/AP-1 and JAK3/MAPKpathways and potently inhibits cytokine-independent cell growth in vitro and tumor cell invasion in vivo.Pathways:Protein Tyrosine Kinase/RTK; Target:JAK References:[1]. Luan HF, Zhao ZB, Zhao QH, Zhu P, Xiu MY, Ji Y.Hydrogen sulfide postconditioning protects isolated rat hearts against ischemia and reperfusion injury mediated by the JAK2/STAT3 survivalpathway.Braz J Med Biol Res. 2012 Oct;45(10):898-905.[2]Grimm S Ott C H?rlacher M Weber D Hoehn A Grune T Advanced glycation end products [2]. Grimm S, Ott C, H?rlacher M, Weber D, Hoehn A, Grune T.Advanced glycation end products-induced formation of immunoproteasomes: involvement of the receptor for AGEs andJak2/STAT1.Biochem J. 2012 Aug 15.[3]. Ferlazzo A, Carvalho ES, Gregorio SF, Power DM, Canario AV, Trischitta F, Fuentes J.Prolactin regulates luminal bicarbonate secretion in the intestine of the sea bream (Sparus auratus L.).J ExpBiol. 2012 Aug 1.[4]. Chang HH, Huang YM, Wu CP, Tang YC, Liu CW, Huang CH, Ho LT, Wu LY, Kuo YC, Kao YH.Endothelin-1 stimulates suppressor of cytokine signaling-3 gene expression in adipocytes.Gen Comp Endocrinol....Caution: Not fully tested. For research purposes onlyMedchemexpress LLCp18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。
Palbociclib_571190-30-2_MSDS_MedChemExpress
MSDS1 Composition7 Accident Release MeasureProduct Name:PalbociclibChemical Name:PROCEDURE(S) OF PERSONAL PRECAUTION(S)-Wear respirator, chemical safety goggles, rubber boots, and heavyrubber gloves.METHODS FOR CLEANING UP-Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area andwash spill site after material pickup is complete.Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-CAS No.:571190-30-28 Accident Release MeasureAppearance:Light yellow to yellow(Solid)Formula:C24H29N7O29 Toxicological InformationSolubility:To the best of our knowledge, the chemical, physical, andtoxicological properties have not been thoroughly investigated.No data available.p p p p DMSO2 Handling and Storage10 Regulary Information3 Stability and Reactivity11Disposal ConsiderationsCLASSIFICATION- Substance not yet fully tested.SAFETY PHASES- 26-36 (In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing.) 36/37/38 (Irritating to eyes,respiratory system and skin.)STABILITY- Stable under normal handling conditions.HANDLING- Do not breathe dust. Avoid contact with eyes,skin,and clothing.Avoid prolonged or repeated exposure.STORAGE- Store in a properly sealed container store at -20℃,shelflife is 2 years.11 Disposal Considerations 4 Hazards Identification12 Transport Information5First Aid RID/ADR- Non-hazardous for road transport. IMDG- Non-hazardous for sea transport.IATA - Non-hazardous for air transport.As specific country, federal, state and local environmentalregulations vary and change frequently we suggest you contact a local, authorized waste disposal contractor for adequate disposal.Special indication of hazards to humans and the environment.Irritating to eyes, respiratory system and skin.MATERIALS TO AVOID- Strong oxidizing agents.REACTIVITY- May emit toxic gasses like Carbon monoxide,Carbon dioxide, Nitrogen oxides upon thermal decomposition.5 First Aid13 Other InformationThe above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Medchemexpress LLC shall not be held liable for any damage resulting from h dli f t t ith th b d tINHALATION- If inhaled, remove to fresh air. If not breathing give, artificial respiration. If breathing is difficult, give oxygen.SKIN CONTACT- In case of contact, immediately wash skin withsoap and copious amounts of water.EYE CONTACT- In case of contact, immediately flush eyes withcopious amounts of water for at least 15 minutes.INGESTION- If swallowed, wash out mouth with water provided person is conscious. Call a physician.6 Fire Fighting Measureshandling or from contact with the above product.EXTINGUISHING MEDIA Water spray- Carbon dioxide, dry chemical powder, or appropriate foam.SPECIAL RISKS Specific Hazard(s)- Emits toxic fumes under fire conditions. SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS Wear self-contained breathing apparatus and protective clothing Caution: Not fully tested. For research purposes onlyMedchemexpress LLCto prevent contact with skin and eyes.18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。
CCG-63802_620112-78-9_MSDS_MedChemExpress
MSDS1 Composition7 Accident Release MeasureProduct Name:CCG-63802Chemical Name:PROCEDURE(S) OF PERSONAL PRECAUTION(S)-Wear respirator, chemical safety goggles, rubber boots, and heavyrubber gloves.METHODS FOR CLEANING UP-Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area andwash spill site after material pickup is complete.2-Benzothiazoleacetonitrile, .alpha.-[[9-methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-CAS No.:620112-78-98 Accident Release MeasureAppearance: light brown to brown(solid)Formula:C26H18N4O2S 9 Toxicological InformationSolubility:To the best of our knowledge, the chemical, physical, andtoxicological properties have not been thoroughly investigated.No data available.p p p p DMSO2 Handling and Storage10 Regulary Information3 Stability and Reactivity11Disposal ConsiderationsCLASSIFICATION- Substance not yet fully tested.SAFETY PHASES- 26-36 (In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing.) 36/37/38 (Irritating to eyes,respiratory system and skin.)STABILITY- Stable under normal handling conditions.HANDLING- Do not breathe dust. Avoid contact with eyes,skin,and clothing.Avoid prolonged or repeated exposure.STORAGE- Store in a properly sealed container store at -20℃,shelflife is 2 years.11 Disposal Considerations 4 Hazards Identification12 Transport Information5First Aid RID/ADR- Non-hazardous for road transport. IMDG- Non-hazardous for sea transport.IATA - Non-hazardous for air transport.As specific country, federal, state and local environmentalregulations vary and change frequently we suggest you contact a local, authorized waste disposal contractor for adequate disposal.Special indication of hazards to humans and the environment.Irritating to eyes, respiratory system and skin.MATERIALS TO AVOID- Strong oxidizing agents.REACTIVITY- May emit toxic gasses like Carbon monoxide,Carbon dioxide, Nitrogen oxides upon thermal decomposition.5 First Aid13 Other InformationThe above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Medchemexpress LLC shall not be held liable for any damage resulting from h dli f t t ith th b d tINHALATION- If inhaled, remove to fresh air. If not breathing give, artificial respiration. If breathing is difficult, give oxygen.SKIN CONTACT- In case of contact, immediately wash skin withsoap and copious amounts of water.EYE CONTACT- In case of contact, immediately flush eyes withcopious amounts of water for at least 15 minutes.INGESTION- If swallowed, wash out mouth with water provided person is conscious. Call a physician.6 Fire Fighting Measureshandling or from contact with the above product.EXTINGUISHING MEDIA Water spray- Carbon dioxide, dry chemical powder, or appropriate foam.SPECIAL RISKS Specific Hazard(s)- Emits toxic fumes under fire conditions. SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS Wear self-contained breathing apparatus and protective clothing Caution: Not fully tested. For research purposes onlyMedchemexpress LLCto prevent contact with skin and eyes.18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。
Famciclovir_104227-87-4_DataSheet_MedChemExpress
Product Name:Famciclovir CAS No.:104227-87-4Cat. No.:HY-17426Product Data SheetMWt:321.33Formula:C14H19N5O4Purity :>98%Solubility:DMSO 64mg/mL; Water 64mg/mL;Ethanol48mg/mL Mechanisms:Biological Activity:Famciclovir(BRL 42810) is a guanine analogue antiviral drug used for the treatment of various h i i f tiPathways:Anti-infection; Target:HSV Ethanol 48mg/mLherpesvirus infections.IC50 Value: Refer to penciclovirTarget: HSV Famciclovir is the diacetyl 6-deoxy analog of the active antiviral compound penciclovir with potential use in the treatment of infections caused by the herpes family of viruses [1]. Famciclovir, a synthetic acyclic guanine derivative, is a prodrug which, after oral administration, is rapidly metabolised to thehighly bioavailable antiviral compound penciclovir [2].in vitro: Famciclovir induced rapid, dose-dependent suppression of viral replication and reduction in alanine aminotransferase (ALT), with greatest efficacy in the 500-mg tid treatment group. HBV DNA References:[1]. Harrell AW, Wheeler SM, Pennick M, Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab Dispos 1993Jan Feb;21(1):1823(),g y g g preduction was maintained throughout the treatment period. ALT also steadily declined during thetreatment period [3]. in vivo: In rat, following ...Metab Dispos. 1993 Jan-Feb;21(1):18-23.[2]. Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeuticefficacy in herpesvirus infections. Drugs. 1995 Aug;50(2):396-415.[3]. Trépo C, Jezek P, Atkinson G, Famciclovir in chronic hepatitis B: results of a dose-finding study.J Hepatol. 2000 Jun;32(6):1011-8.[4]. Filer CW, Ramji JV, Allen GD, Metabolic and pharmacokinetic studies following oraladministration of famciclovir to the rat and dog. Xenobiotica. 1995 May;25(5):477-90.[5]. Wutzler P, Ulbricht A, F?rber I. Antiviral efficacies of famciclovir, valaciclovir, and brivudin in disseminated herpes simplex virus type 1 inf...Caution: Not fully tested. For research purposes onlyMedchemexpress LLCp p yp18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。
PHA-665752_477575-56-7_DataSheet_MedChemExpress
Product Name:PHA-665752CAS No.:477575-56-7Cat. No.:HY-11107MWt:641.61Formula:C32H34Cl2N4O4S Purity :>98%Solubility:Mechanisms:Biological Activity:Pathways:Protein Tyrosine Kinase/RTK; Target:c-Met/HGFR Product Data SheetDMSO ≥125mg/mL Water<1.2mg/mL Ethanol ≥124mg/mLg y References:Caution: Not fully tested. For research purposes onlyMedchemexpress LLC[1]. Puri et al (2007) A selective small molecule inhibitor of c-Met, PHA665752, inhibitstumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67 3529.[2]. Wang K, Zhuang Y, Liu C, Li Y.Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling.Arch Biochem Biophys. 2012 Oct 1;526(1):38-43. Epub 2012 Jul 20.[3]. Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR.MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.Mol Cancer Ther. 2012Mar;11(3):660-9. Epub 2012 Jan 11.[4]. Bu R, Uddin S, Ahmed M, Hussain AR, Alsobhi S, Amin T, Al-Nuaim A, Al-Dayel F, Abubaker J,Bavi P, Al-Kuraya KS.c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death.Mol ...PHA-665752 is potent, selective and ATP-competitive inhibitor of MET kinase. (IC50 values are 9,68, 200, 1400, 3000, 3800 and 6000 nM for MET, Ron, Flk-1, c-abl, FGFR1, EGFR and c-src respectively and > 10000 nM for IGF-IR, PDGFR, AURORA2, PKA, PKB α, p38α, MK2 and MK3).Antitumor agent; PHA-665752 inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S AE m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c om。